Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
Julien Cherfils-Vicini, … , Catherine Sautès-Fridman, Isabelle Cremer
Julien Cherfils-Vicini, … , Catherine Sautès-Fridman, Isabelle Cremer
Published March 8, 2010
Citation Information: J Clin Invest. 2010;120(4):1285-1297. https://doi.org/10.1172/JCI36551.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 9

Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance

  • Text
  • PDF
Abstract

Compelling evidence suggests that inflammation, cell survival, and cancer are linked, with a central role played by NF-κB. Recent studies implicate some TLRs in tumor development based on their ability to facilitate tumor growth; however, to our knowledge, involvement of neither TLR7 nor TLR78 has yet been demonstrated. Here we have demonstrated expression of TLR7 and TLR8, the natural receptors for single-stranded RNA, by tumor cells in human lung cancer in situ and in human lung tumor cell lines. Stimulation with TLR7 or TLR8 agonists led to activated NF-κB, upregulated expression of the antiapoptotic protein Bcl-2, increased tumor cell survival, and chemoresistance. Transcriptional analysis performed on human primary lung tumor cells and TLR7- or TLR8-stimulated human lung tumor cell lines revealed a gene expression signature suggestive of chronic stimulation of tumor cells by TLR ligands in situ. Together, these data emphasize that TLR signaling can directly favor tumor development and further suggest that researchers developing anticancer immunotherapy using TLR7 or TLR8 agonists as adjuvants should take into account the expression of these TLRs in lung tumor cells.

Authors

Julien Cherfils-Vicini, Sophia Platonova, Mélanie Gillard, Ludivine Laurans, Pierre Validire, Rafaele Caliandro, Pierre Magdeleinat, Fathia Mami-Chouaib, Marie-Caroline Dieu-Nosjean, Wolf-Herman Fridman, Diane Damotte, Catherine Sautès-Fridman, Isabelle Cremer

×

Figure 6

TLR7 and TLR8 induce chemoresistance of lung tumor cells.

Options: View larger image (or click on image) Download as PowerPoint
TLR7 and TLR8 induce chemoresistance of lung tumor cells.
A549 (A, C, an...
A549 (A, C, and E) or SK-MES cells (B, D, and F) were cultured in 6-well plates with or without loxoribine (added at days 0, 3, 6, and 9). Cells were then treated or not with cycloheximide, cisplatine, carboplatine, doxorubicine, or Navelbine at day 12 (A–D), or treated or not with cisplatine or carboplatine in association with Navelbine or doxorubicine (E and F). (A and B) The colony number (shown below) was determined after Crystal Violet coloration. (C–F) Cell viability was analyzed at day 15 by the surviving fraction, calculated as [no. colonies after chemotherapy treatment/(no. cells seeded at day 0 × PE)] × 100, where PE is plating efficiency (calculated as no. colonies/no. cells seeded at day 0). Data represent mean ± SD from 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus unstimulated, Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 22 patents
161 readers on Mendeley
See more details